Antares Secures $470 Million in Latest Series C Funding Round

Antares secured $470 million in its latest Series C, adding another data point to the Healthcare & Life Sciences funding market.

Antares Raises $470 million in Funding

Antares Raises $470M Series C To Deploy Nuclear Microreactors For Critical Missions. Paradigm is thrilled to back this team as they help to restore energy dominance in the U.S." The capital, which includes $370 million in equity and $100 million in debt, comes weeks after Antares took its Mark-0 reactor critical at Idaho National Laboratory.

Investors Behind the Funding

The round was backed by Paradigm. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Antares operates in Healthcare & Life Sciences. Antares's financing adds to recent private-market activity.

Strategic Use of Funds

Deploy Nuclear Microreactors For Critical Missions.

Looking Ahead

Jordan and the Antares team just achieved the first private advanced reactor criticality in decades with a factory built microreactor,

Source reference: original announcement/article.